{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:14:33Z","timestamp":1786986873414,"version":"build-2736575974"},"reference-count":58,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1016\/j.clinthera.2010.09.003","type":"journal-article","created":{"date-parts":[[2010,12,29]],"date-time":"2010-12-29T04:15:21Z","timestamp":1293596121000},"page":"1681-1703","source":"Crossref","is-referenced-by-count":36,"title":["Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-\u03b1 inhibitor"],"prefix":"10.1016","volume":"32","author":[{"given":"Eric G.","family":"Boyce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenana","family":"Halilovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oby","family":"Stan-Ugbene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2010.09.003_bib1","series-title":"Simponi [package insert]","year":"2009"},{"key":"10.1016\/j.clinthera.2010.09.003_bib2","series-title":"Enbrel [package insert]","year":"2010"},{"key":"10.1016\/j.clinthera.2010.09.003_bib3","series-title":"Remicade [package insert]","year":"2009"},{"key":"10.1016\/j.clinthera.2010.09.003_bib4","series-title":"Humira [package insert]","year":"2010"},{"key":"10.1016\/j.clinthera.2010.09.003_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007848","article-title":"Biologics for rheumatoid arthritis: An overview of Cochrane reviews","volume":"4","author":"Singh","year":"2009","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.clinthera.2010.09.003_bib6","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.coph.2010.01.005","article-title":"Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases","volume":"10","author":"Taylor","year":"2010","journal-title":"Curr Opin Pharmacol."},{"key":"10.1016\/j.clinthera.2010.09.003_bib7","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clinthera.2010.09.003_bib8","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/art.23383","article-title":"Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebocontrolled, dose-ranging study","volume":"58","author":"Kay","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clinthera.2010.09.003_bib9","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/ard.2008.099010","article-title":"Golimumab, a human antibody to tumour necrosis factor a given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: The GO-FORWARD Study","volume":"68","author":"Keystone","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.clinthera.2010.09.003_bib10","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/art.27348","article-title":"Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study","volume":"62","author":"Kremer","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clinthera.2010.09.003_bib11","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","article-title":"Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER Study): A multicentre, randomised, double-blind, placebo-controlled, phase III trial [published correction appears in Lancet. 2009;374:1422]","volume":"374","author":"Smolen","year":"2009","journal-title":"Lancet."},{"key":"10.1016\/j.clinthera.2010.09.003_bib12","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/art.23721","article-title":"American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis","volume":"59","author":"Saag","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clinthera.2010.09.003_bib13","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/art.24638","article-title":"Golimumab, a human anti-tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for earlyonset rheumatoid arthritis","volume":"60","author":"Emery","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clinthera.2010.09.003_bib14","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.3899\/jrheum.080755","article-title":"E-selectin, interleukin 18, serum amyloid \u03b1, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy","volume":"36","author":"Visvanathan","year":"2009","journal-title":"J Rheumatol."},{"key":"10.1016\/j.clinthera.2010.09.003_bib15","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.3899\/jrheum.081188","article-title":"Which measures of inflammation to use? A comparison of erythrocyte sedimentation rate and C-reactive protein measurements from randomized clinical trials of golimumab in rheumatoid arthritis [published correction appears in J Rheumatol. 2009;36:2625]","volume":"36","author":"Crowson","year":"2009","journal-title":"J Rheumatol."},{"issue":"1","key":"10.1016\/j.clinthera.2010.09.003_bib16","first-page":"CD008341","article-title":"Golimumab for rheumatoid arthritis","author":"Singh","year":"2010","journal-title":"Cochrane Database Syst Rev."},{"issue":"3","key":"10.1016\/j.clinthera.2010.09.003_bib17","first-page":"CD005113","article-title":"Adalimumab for treating rheumatoid arthritis","author":"Navarro-Sarabia","year":"2005","journal-title":"Cochrane Database Syst Rev."},{"issue":"3","key":"10.1016\/j.clinthera.2010.09.003_bib18","first-page":"CD003785","article-title":"Infliximab for the treatment of rheumatoid arthritis","author":"Blumenauer","year":"2002","journal-title":"Cochrane Database Syst Rev."},{"issue":"3","key":"10.1016\/j.clinthera.2010.09.003_bib19","first-page":"CD004525","article-title":"Etanercept for the treatment of rheumatoid arthritis","author":"Blumenauer","year":"2003","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.clinthera.2010.09.003_bib20","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jaad.2008.02.040","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics","volume":"58","author":"Gottlieb","year":"2008","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.clinthera.2010.09.003_bib21","first-page":"1417","article-title":"Systematic review of treatments for psoriatic arthritis: An evidence based approach and basis for treatment guidelines","volume":"33","author":"Kavanaugh","year":"2006","journal-title":"J Rheumatol."},{"key":"10.1016\/j.clinthera.2010.09.003_bib22","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/art.24403","article-title":"Golimumab, a new human tumor necrosis factor alpha anti- body, administered every 4 weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study","volume":"60","author":"Kavanaugh","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clinthera.2010.09.003_bib23","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clinthera.2010.09.003_bib24","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clinthera.2010.09.003_bib25","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/ard.2005.041137","article-title":"ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"65","author":"Zochling","year":"2006","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.clinthera.2010.09.003_bib26","unstructured":"Deodhar A, Braun J, Inman RD, et al. Golimumab reduces sleep disturbance in patients with active ankylosing spondylitis: Results from a randomized, placebo-controlled trial [published online ahead of print April 21, 2010]. Arthritis Care Res (Hoboken)."},{"key":"10.1016\/j.clinthera.2010.09.003_bib27","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/ard.2007.087270","article-title":"Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: Longterm results from the ATLAS trial","volume":"68","author":"van der Heijde","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.clinthera.2010.09.003_bib28","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clinthera.2010.09.003_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003574.pub2","article-title":"Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease","volume":"41","author":"Akobeng","year":"2003","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.clinthera.2010.09.003_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006893","article-title":"Tumor necrosis factor-alpha antibody for maintenance ofremission in Crohn's disease","volume":"1","author":"Behm","year":"2008","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.clinthera.2010.09.003_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005112.pub2","article-title":"Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis","volume":"3","author":"Lawson","year":"2006","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.clinthera.2010.09.003_bib32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/11531980-000000000-00000","article-title":"Newer biological agents in rheumatoid arthritis impact on health-related quality of life and productivity","volume":"70","author":"Strand","year":"2010","journal-title":"Drugs."},{"key":"10.1016\/j.clinthera.2010.09.003_bib33","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1177\/0091270006298188","article-title":"Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis","volume":"47","author":"Zhou","year":"2007","journal-title":"J Clin Pharmacol."},{"issue":"Suppl 82","key":"10.1016\/j.clinthera.2010.09.003_bib34","first-page":"25","article-title":"Comparative overview of safety of the biologicals in rheumatoid arthritis","volume":"36","author":"Khraishi","year":"2009","journal-title":"J Rheumatol."},{"key":"10.1016\/j.clinthera.2010.09.003_bib35","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: A comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol Ther."},{"key":"10.1016\/j.clinthera.2010.09.003_bib36","first-page":"274","article-title":"Characterization of golimumab (CNTO 148), a novel monoclonal antibody specific for human TNFalpha","volume":"56","author":"Shealy","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clinthera.2010.09.003_bib37","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1177\/0091270009339192","article-title":"Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-\u03b1 human monoclonal antibody, in patients with psoriatic arthritis","volume":"49","author":"Xu","year":"2009","journal-title":"J Clin Pharmacol."},{"issue":"Suppl II","key":"10.1016\/j.clinthera.2010.09.003_bib38_1","first-page":"627","article-title":"Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha monoclonal antibody in patients with ankylosing spondylitis [psoriatic arthritis, rheumatoid arthritis]. EULAR 2008 Abstract# AB0675, SAT0316, FRI0149","volume":"67","author":"Xu","year":"2008","journal-title":"Ann Rheum Dis."},{"issue":"Suppl II","key":"10.1016\/j.clinthera.2010.09.003_bib38_2","first-page":"533","article-title":"Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha monoclonal antibody in patients with ankylosing spondylitis [psoriatic arthritis, rheumatoid arthritis]. EULAR 2008 Abstract# AB0675, SAT0316, FRI0149","volume":"67","author":"Xu","year":"2008","journal-title":"Ann Rheum Dis."},{"issue":"Suppl II","key":"10.1016\/j.clinthera.2010.09.003_bib38_3","first-page":"334","article-title":"Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha monoclonal antibody in patients with ankylosing spondylitis [psoriatic arthritis, rheumatoid arthritis]. EULAR 2008 Abstract# AB0675, SAT0316, FRI0149","volume":"67","author":"Xu","year":"2008","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.clinthera.2010.09.003_bib39","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1177\/0091270009340782","article-title":"Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects","volume":"50","author":"Xu","year":"2010","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.clinthera.2010.09.003_bib40","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1177\/0091270009355162","article-title":"Lack of racial differences in the pharmacokinetics of subcutaneous golimumab in healthy Japanese and Caucasian male subjects","volume":"50","author":"Ling","year":"2010","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.clinthera.2010.09.003_bib41","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1345\/aph.19126","article-title":"The pharmacokinetics of etanercept in healthy volunteers","volume":"34","author":"Korth-Bradley","year":"2000","journal-title":"Ann Pharmacother."},{"key":"10.1016\/j.clinthera.2010.09.003_bib43","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clinthera.2010.09.003_bib44","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clinthera.2010.09.003_bib45","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eightjoint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clinthera.2010.09.003_bib46","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1002\/art.24123","article-title":"Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR\/ACR collaborative recommendations","volume":"59","author":"Aletaha","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clinthera.2010.09.003_bib47","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1067\/S0190-9622(03)00910-1","article-title":"Nail Psoriasis Severity Index: A useful tool for evaluation of nail psoriasis","volume":"49","author":"Rich","year":"2003","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.clinthera.2010.09.003_bib48","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F","article-title":"Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis","volume":"44","author":"Anderson","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clinthera.2010.09.003_bib49","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol."},{"key":"10.1016\/j.clinthera.2010.09.003_bib51","first-page":"2281","article-title":"A new approach to defining functional ability in ankylosing spondylitis: The development of the Bath Ankylosing Spondylitis Functional Index","volume":"21","author":"Calin","year":"1994","journal-title":"J Rheumatol."},{"key":"10.1016\/j.clinthera.2010.09.003_bib53","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/art.20790","article-title":"ASessment in Ankylosing Spondylitis International Working Group\/Spondylitis Association of America recommendations for conducting clinical trials in ankylosing spondylitis","volume":"52","author":"Van der Heijde","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clinthera.2010.09.003_bib54","first-page":"721","article-title":"A case of psoriasiform eruption triggered by tumor necrosis factor-alpha antagonist therapy","volume":"46","author":"Yoon","year":"2008","journal-title":"Korean J Dermatol."},{"key":"10.1016\/j.clinthera.2010.09.003_bib55","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1600-0897.2007.00499.x","article-title":"Effects of an anti-TNF-alpha monoclonal antibody, administered throughout pregnancy and lactation, on the development of the macaque immune system","volume":"58","author":"Martin","year":"2007","journal-title":"Am J Reprod Immunol."},{"key":"10.1016\/j.clinthera.2010.09.003_bib56","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2010.09.003_bib57","unstructured":"Zidi I, Bouaziz A, Mnif W, et al. Golimumab and malignancies: True or false association [published online ahead of print April 7, 2010]? Med Oncol."},{"key":"10.1016\/j.clinthera.2010.09.003_bib58","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/art.23281","article-title":"Does tumor necrosis factor a inhibition promote or prevent heart failure in patients with rheumatoid arthritis?","volume":"58","author":"Listing","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clinthera.2010.09.003_bib59","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1164\/rccm.200809-1512OC","article-title":"A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma","volume":"179","author":"Wenzel","year":"2009","journal-title":"Am J Respir Crit Care Med."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291810003127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291810003127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T20:20:54Z","timestamp":1544041254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291810003127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":58,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0149291810003127"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2010.09.003","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}